Stephen Chia
University of British Columbia · 31 works · 5,050 citations · h-index 16
Top works
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
- Ribociclib plus Endocrine Therapy in Early Breast Cancer
- Locally Advanced and Inflammatory Breast Cancer
- Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas
- First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
- A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors
- Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
- Encapsulated apocrine papillary carcinoma of the breast—a tumour of uncertain malignant potential: report of five cases
- Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers
- The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities
- Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D
- Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer
- Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
- PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus Fulvestrant in Postmenopausal Women With Endocrine-resistant HR+/HER2- Advanced Breast Cancer: First Results From the Randomized, Phase III BELLE-2 Trial
- Abstract PD13-05: Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2— advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses
- The Development of a Standardized Software Platform to Support Provincial Population-Based Cancer Outcomes Units for Multiple Tumour Sites: OaSIS - Outcomes and Surveillance Integration System